Akoya to Participate at Three Upcoming Investor Conferences
MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
News
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PSTSAN DIEGO, Nov....
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
Company to host an investor conference call and webcast at 4:30pm ET on that dayNEW YORK, Nov. 03, 2022 (GLOBE...
Galecto to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in...
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression PatientsBURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022...
Stedical Scientific continues its mission to accelerate the global distribution of disruptive innovations in healthcare
CARLSBAD, Calif. and SHANGHAI, China, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Stedical Scientific announced today that it has secured three...
Myia Health Collaborates with DispatchHealth to Empower Clinicians with Virtual Care Platform for Continuous Patient Monitoring
DispatchHealth clinicians will have access to near real-time insights to optimize patient outcomes and clinical operationsSAN FRANCISCO, Nov. 02, 2022...
PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
ALA-002 is PharmAla’s lead drug candidate, showing exceptional safety and efficacy in preclinical rodent modelsVANCOUVER, British Columbia, Nov. 02, 2022...
NEXGEL to Report Third Quarter 2022 Financial Results on November 8th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 02, 2022 (GLOBE...
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...
Aleafia Health to Announce Fiscal Year 2023 Second Quarter Results
TORONTO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will...
Evoke Pharma to Report Third Quarter Results on November 9, 2022
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...
Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On...
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device
Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered...
CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing...
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage...